Bayer's Schering scheme rules it out of Pfizer bid

June 2006
ICIS Chemical Business;6/12/2006, Vol. 1 Issue 23, p4
Trade Publication
The article reports on the bid proposal of Bayer for the acquisition of the over-the-counter drugs business of Pfizer, which is Schering. Before the proposed Schering deal, Bayer had been concentrating on building its over-the-counter segment, and is believed to have bid for the Boots activities that later went to Reckitt Benckiser. Bayer chairman Werner Wenning said that they are convinced that the merger will create a healthcare heavyweight of international standing.


Related Articles

  • Bayer to Buy Eastern European OTC Business. Walsh, Kerri // Chemical Week;3/17/2008, Vol. 170 Issue 9, p17 

    The article reports on the plan of Bayer to buy the over-the-counter (OTC) business of Sagmel of Libertyville, Illinois. Sagmel is a privately held pharmaceutical company, and reported sales of $122 million for the year beginning October 2006. The transaction will include Sagmel's assets related...

  • Bayer Buys Roche Consumer Division. Houlton, Sarah // Pharmaceutical Executive;Sep2004, Vol. 24 Issue 9, p24 

    Reports on the acquisition of Roche's consumer division by Bayer, a pharmaceutical company. Plan of Bayer to double its over-the-counter drug sales; Increase in consumer health; Reputation of the firms in the drug industry.

  • Bayer: OTC purchase fails to address bigger picture.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p37 

    Reports on Bayer's acquisition of Roche's over-the-counter (OTC) business. Projected annual sales of the expanded OTC business of Bayer; Speculations on the future of Bayer's overall pharamaceutical business; Problems confronting Bayer's ethical business.

  • Degussa in the Running for H&R.  // Chemical Week;4/24/2002, Vol. 164 Issue 17, p14 

    Reports that Bayer has confirmed that Degussa is among the several bidders conducting diligence for Haarmann & Reimer (H&R), the flavors and fragrances subsidiary of Bayer. Price in which Bayer wants to sell H&R.

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Nov2006, Vol. 5 Issue 11, p3 

    The article focuses on various developments related to the pharmaceutical industry in several countries. Pfizer Inc. has purchased Oxford, England-based vaccine manufacturer PowderMed Ltd. Pharmaceutical firm Bayer AG has admitted that it made a mistake by failing to inform the U.S. Food and...

  • Reckitt link to Pfizer bid. Robinson, Simon // ICIS Chemical Business;3/27/2006, Vol. 1 Issue 12, p10 

    The article reports that British household cleaning and over-the-counter (OTC) medicines producer Reckitt-Benckiser has been speculated as a bidder for Consumer Healthcare, the OTC medicines arm of Pfizer, in 2006. Reckitt was said to have engaged advisors including banks Merrill Lynch and...

  • J&J takeover threat to JWT Pfizer account. Stokes, Barny // Marketing Week;6/29/2006, Vol. 29 Issue 26, p11 

    The article reports on the acquisition of the over-the-counter healthcare business of Pfizer Inc. by Johnson & Johnson company in Great Britain. The brands included in the $16.6 billion acquisition include Listerine mouthwash and Sudafed decongestant. Meanwhile, Johnson & Johnson is planning to...

  • Roche sells OTC business to Bayer. Kumar, Rajesh // New Zealand Doctor;12/15/2004, p11 

    Reports on the acquisition of the over-the-counter (OTC) medicines business of Roche by Bayer Healthcare. Cost of the deal; Estimated sales of the combined OTC businesses of Bayer Consumer Care and Roche Consumer Health; Company which was offered to outlicense U.S. non-prescription rights of...

  • Bayer in Exclusive Talks To Acquire Roche's OTC Unit.  // Chemical Market Reporter;7/5/2004, Vol. 266 Issue 1, p6 

    Reports on the negotiation between Bayer AG and Roche Pharmaceuticals for the acquisition of the pharmaceutical company's over-the-counter (OTC) medicines. Significance of the acquisition to the market share of Bayer AG in the OTC drug market; Question on the financing of the deal by Bayer AG;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics